Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI). It has Long-Acting Beta2 Agonist collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-238-9600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$261 million
Profitability
Miscellaneous
Employees12
OptionableOptionable
Innoviva (NASDAQ:INVA) Frequently Asked Questions
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "INVA."
How were Innoviva's earnings last quarter?
Innoviva Inc (NASDAQ:INVA) posted its earnings results on Wednesday, October, 31st. The biotechnology company reported $0.43 earnings per share for the quarter, missing analysts' consensus estimates of $0.49 by $0.06. The biotechnology company earned $61.70 million during the quarter, compared to analysts' expectations of $64 million. Innoviva had a net margin of 151.36% and a negative return on equity of 253.88%. The company's revenue for the quarter was up 27.0% compared to the same quarter last year. During the same period last year, the business posted $0.21 earnings per share. View Innoviva's Earnings History.
When is Innoviva's next earnings date?
What price target have analysts set for INVA?
2 analysts have issued 1 year target prices for Innoviva's stock. Their forecasts range from $16.00 to $16.00. On average, they expect Innoviva's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price. View Analyst Price Targets for Innoviva.
What is the consensus analysts' recommendation for Innoviva?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innoviva.
Has Innoviva been receiving favorable news coverage?
Headlines about INVA stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Innoviva earned a daily sentiment score of 0.3 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the immediate future.
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include Amarin (AMRN), Alkermes (ALKS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Array Biopharma (ARRY), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), TESARO (TSRO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Agios Pharmaceuticals (AGIO), Evotec (EVTCY), HUTCHISON CHINA/S (HCM) and Emergent Biosolutions (EBS).
Who are Innoviva's key executives?
Innoviva's management team includes the folowing people:
- Mr. Geoffrey Hulme, Interim Principal Exec. Officer
- Ms. Marianne Zhen, Chief Accounting Officer (Age 50)
- Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
- Dr. Kevin Kwok, Head of Talent Acquisition & Strategy
- Dr. Edmund J. Moran Ph.D., VP and R&D Program Leader (Age 58)
Who are Innoviva's major shareholders?
Innoviva's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.67%), LSV Asset Management (2.38%), Dimensional Fund Advisors LP (2.31%), D. E. Shaw & Co. Inc. (1.94%), Connor Clark & Lunn Investment Management Ltd. (1.27%) and MERIAN GLOBAL INVESTORS UK Ltd (1.27%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar and Theodore J Jr Witek. View Institutional Ownership Trends for Innoviva.
Which major investors are selling Innoviva stock?
INVA stock was sold by a variety of institutional investors in the last quarter, including Connor Clark & Lunn Investment Management Ltd., Acadian Asset Management LLC, MERIAN GLOBAL INVESTORS UK Ltd, BlackRock Inc., Gotham Asset Management LLC, Virginia Retirement Systems ET AL, Chicago Equity Partners LLC and KBC Group NV. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie and Theodore J Jr Witek. View Insider Buying and Selling for Innoviva.
Which major investors are buying Innoviva stock?
INVA stock was bought by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Penserra Capital Management LLC, LSV Asset Management, Oregon Public Employees Retirement Fund, Ackerman Capital Advisors LLC, WINTON GROUP Ltd, Two Sigma Investments LP and SG Americas Securities LLC. View Insider Buying and Selling for Innoviva.
How do I buy shares of Innoviva?
Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innoviva's stock price today?
One share of INVA stock can currently be purchased for approximately $14.67.
How big of a company is Innoviva?
Innoviva has a market capitalization of $1.48 billion and generates $261 million in revenue each year. The biotechnology company earns $395.06 million in net income (profit) each year or $3.53 on an earnings per share basis. Innoviva employs 12 workers across the globe.
What is Innoviva's official website?
How can I contact Innoviva?
Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]
MarketBeat Community Rating for Innoviva (NASDAQ INVA)
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
